Abstract
Tackling impaired bioenergetics in multiple sclerosis (MS) has been recently recognized as an innovative approach with therapeutic potential. Guanidinoacetic acid (GAA) is an experimental nutrient that plays a significant role in high-energy phosphate metabolism. The preliminary trials suggest beneficial effects of supplemental GAA in MS, with GAA augments biomarkers of brain energy metabolism and improves patient-reported features of the disease. GAA can also impact other metabolic footprints of MS, including demyelination, oxidative stress, and GABA-glutamate imbalance. In this mini-review article, we summarize studies evaluating GAA effectiveness in MS, explore mechanisms of GAA action, and discuss the challenges of using dietary GAA as an element of MS therapy.
Subject
Behavioral Neuroscience,Biological Psychiatry,Psychiatry and Mental health,Neurology,Neuropsychology and Physiological Psychology
Reference45 articles.
1. Metabolic defects in multiple sclerosis.;Adiele;Mitochondrion,2019
2. Effects of delivering guanidinoacetic acid or its prodrug to the neural tissue: possible relevance for creatine transporter deficiency.;Adriano;Brain Sci.,2022
3. Performance, carcass yield, muscle amino acid profile, and levels of brain neurotransmitters in aged laying hens fed diets supplemented with guanidinoacetic acid.;Ahmed-Farid;Animals,2021
4. Glycocyamine betaine as an adjunct in the treatment of neuromuscular disease patients.;Aldes;J. Ark. Med. Soc.,1957
5. Dietary supplementation of guanidinoacetic acid improves growth, biochemical parameters, antioxidant capacity and cytokine responses in Nile tilapia (Oreochromis niloticus).;Aziza;Fish Shellfish Immunol.,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献